taurine has been researched along with Becker Muscular Dystrophy in 15 studies
| Excerpt | Relevance | Reference |
|---|---|---|
| "A milder form of the disease, Becker muscular dystrophy (BMD), is characterised by the presence of a semi-functional truncated dystrophin, or the full-length dystrophin at reduced level." | 2.43 | [Pharmacological treatments for Duchenne and Becker dystrophies]. ( de la Porte, S; Voisin, V, 2005) |
| "Taurine is an amino acid abundantly present in heart and skeletal muscle." | 1.51 | A long-term treatment with taurine prevents cardiac dysfunction in mdx mice. ( Bove, M; Camerino, GM; Capogrosso, RF; Conte, E; De Bellis, M; De Luca, A; Mantuano, P; Mele, A; Morgese, MG; Pierno, S; Rana, F; Rolland, JF; Sanarica, F; Trabace, L, 2019) |
| "Taurine treatment of mdx mice only altered ncRNA levels when administered from 18 days to 6 weeks of age, but a deficiency in tRNA levels was rectified earlier in mdx skeletal muscles treated from 14 days to 3 weeks." | 1.48 | Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment. ( Butchart, LC; Filipovska, A; Grounds, MD; Rossetti, G; Terrill, JR; White, R, 2018) |
| "Taurine treatment also reduced protein thiol oxidation and was overall more effective, as OTC treatment reduced body and muscle weight, suggesting some adverse effects of this drug." | 1.43 | Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy. ( Arthur, PG; Graves, JA; Grounds, MD; Pinniger, GJ; Terrill, JR, 2016) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (20.00) | 29.6817 |
| 2010's | 9 (60.00) | 24.3611 |
| 2020's | 3 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Merckx, C | 1 |
| Cosemans, G | 1 |
| Zschüntzsch, J | 1 |
| Raedt, R | 1 |
| Schmidt, J | 1 |
| De Paepe, B | 1 |
| De Bleecker, JL | 1 |
| Ren, X | 1 |
| Xu, H | 3 |
| Barker, RG | 3 |
| Lamb, GD | 1 |
| Murphy, RM | 3 |
| Terrill, JR | 5 |
| Webb, SM | 1 |
| Arthur, PG | 4 |
| Hackett, MJ | 1 |
| Wyckelsma, VL | 1 |
| Frankish, BP | 1 |
| Butchart, LC | 1 |
| Rossetti, G | 1 |
| White, R | 1 |
| Filipovska, A | 1 |
| Grounds, MD | 4 |
| Mele, A | 1 |
| Mantuano, P | 2 |
| De Bellis, M | 2 |
| Rana, F | 1 |
| Sanarica, F | 1 |
| Conte, E | 1 |
| Morgese, MG | 1 |
| Bove, M | 1 |
| Rolland, JF | 2 |
| Capogrosso, RF | 3 |
| Pierno, S | 2 |
| Camerino, GM | 2 |
| Trabace, L | 1 |
| De Luca, A | 4 |
| Boyatzis, A | 1 |
| Pinniger, GJ | 1 |
| Graves, JA | 1 |
| Cozzoli, A | 2 |
| Massari, AM | 1 |
| Sblendorio, VT | 2 |
| Tamma, R | 1 |
| Giustino, A | 1 |
| Nico, B | 2 |
| Montagnani, M | 1 |
| Longo, V | 1 |
| Simonetti, S | 1 |
| Liantonio, A | 1 |
| Conte Camerino, D | 1 |
| Voisin, V | 1 |
| de la Porte, S | 1 |
| Gulston, MK | 1 |
| Rubtsov, DV | 1 |
| Atherton, HJ | 1 |
| Clarke, K | 1 |
| Davies, KE | 1 |
| Lilley, KS | 1 |
| Griffin, JL | 1 |
2 reviews available for taurine and Becker Muscular Dystrophy
| Article | Year |
|---|---|
Pre-clinical trials in Duchenne dystrophy: what animal models can tell us about potential drug effectiveness.
Topics: Adrenal Cortex Hormones; Animals; Chloride Channels; Disease Progression; Dystrophin; Humans; Insuli | 2002 |
[Pharmacological treatments for Duchenne and Becker dystrophies].
Topics: Adrenal Cortex Hormones; Adult; Aminoglycosides; Animals; Carnitine; Child; Child, Preschool; Creati | 2005 |
13 other studies available for taurine and Becker Muscular Dystrophy
| Article | Year |
|---|---|
Description of Osmolyte Pathways in Maturing
Topics: Animals; Inositol; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle, Skeletal; Muscular Dystrophy, | 2022 |
Elevated MMP2 abundance and activity in mdx mice are alleviated by prenatal taurine supplementation.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Female; Male; Matrix Metalloproteinase 2; Matr | 2020 |
Investigation of the effect of taurine supplementation on muscle taurine content in the mdx mouse model of Duchenne muscular dystrophy using chemically specific synchrotron imaging.
Topics: Animals; Dietary Supplements; Disease Models, Animal; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Mu | 2020 |
Mitochondrial content is preserved throughout disease progression in the mdx mouse model of Duchenne muscular dystrophy, regardless of taurine supplementation.
Topics: Animals; Citrate (si)-Synthase; Dietary Supplements; Disease Models, Animal; Disease Progression; El | 2018 |
Elevated GLUT4 and glycogenin protein abundance correspond to increased glycogen content in the soleus muscle of mdx mice with no benefit associated with taurine supplementation.
Topics: Animals; Glucose Transporter Type 4; Glucosyltransferases; Glycogen; Glycoproteins; Male; Mice; Mice | 2018 |
Expression patterns of regulatory RNAs, including lncRNAs and tRNAs, during postnatal growth of normal and dystrophic (mdx) mouse muscles, and their response to taurine treatment.
Topics: Animals; Disease Models, Animal; Female; Gene Expression Regulation; Male; Mice; Mice, Inbred C57BL; | 2018 |
A long-term treatment with taurine prevents cardiac dysfunction in mdx mice.
Topics: Animals; Drinking; Hindlimb; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Contraction; M | 2019 |
Treatment with the cysteine precursor l-2-oxothiazolidine-4-carboxylate (OTC) implicates taurine deficiency in severity of dystropathology in mdx mice.
Topics: Acetylcysteine; Animals; Disease Models, Animal; Male; Mice; Mice, Inbred C57BL; Muscular Dystrophy, | 2013 |
Taurine deficiency, synthesis and transport in the mdx mouse model for Duchenne Muscular Dystrophy.
Topics: Animals; Biological Transport; Chromatography, High Pressure Liquid; Cysteine; Disease Models, Anima | 2015 |
Increasing taurine intake and taurine synthesis improves skeletal muscle function in the mdx mouse model for Duchenne muscular dystrophy.
Topics: Animals; Disease Models, Animal; Female; Male; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscle Co | 2016 |
Assessment of resveratrol, apocynin and taurine on mechanical-metabolic uncoupling and oxidative stress in a mouse model of duchenne muscular dystrophy: A comparison with the gold standard, α-methyl prednisolone.
Topics: Acetophenones; Animals; Antioxidants; Disease Models, Animal; Male; Methylprednisolone; Mice; Mice, | 2016 |
Evaluation of potential synergistic action of a combined treatment with alpha-methyl-prednisolone and taurine on the mdx mouse model of Duchenne muscular dystrophy.
Topics: Animals; Chromatography, High Pressure Liquid; Creatine Kinase; Disease Models, Animal; Drug Synergi | 2011 |
A combined metabolomic and proteomic investigation of the effects of a failure to express dystrophin in the mouse heart.
Topics: Aging; Animals; Dystrophin; Male; Metabolism; Mice; Mice, Inbred C57BL; Mice, Inbred mdx; Muscular D | 2008 |